ARTICLE | Clinical News
Lymphoseek: Phase III data
May 9, 2011 7:00 AM UTC
Top-line data from the open-label, U.S. Phase III NEO3-09 trial in over 150 patients showed that Lymphoseek met the primary endpoint of 100% concordance with vital blue dye in over 200 nodes. Addition...